Home

Review

Read time: 3 min

Congress highlights

Does inflammation really contribute to migraine pain?

At a lively debate at the AHS 2022 hybrid congress in Denver, Professor Dan Levy of the Beth Israel...

Alzheimer's Disease

Read time: 4 min

Congress highlights

Biofluid-based biomarkers – realizing their potential in Alzheimer’s disease

Henrik Zetterberg, University of Gothenberg, Sweden and University College London, UK, during the...

Biomarkers - the Future of Diagnosis in Psychiatry?

Diagnosis of psychiatric disorders currently depends on clinical criteria. In the future the hope...

Biomarkers - the Future of Diagnosis in Psychiatry?

Read time: 3 min

Satellite symposium

CGRP antibodies can help alleviate difficult-to-treat migraine

Clinicians and researchers are continually expanding our understanding of disease mechanisms and...

Alzheimer's Disease

Read time: 3 min

Congress highlights

Which tau biomarkers are most informative in AD?

Aggregates of hyperphosphorylated and C-terminally truncated microtubule-associated tau protein are...

Read time: 4 min

Satellite symposium

Emotional blunting: unresolved MDD symptom or effect of treatment?

Some evidence suggests that emotional blunting is a side effect of therapy, but other evidence...

Read time: 4 min

Satellite symposium

Congress highlights

Patient goals and measuring outcome crucial in MDD

Asking people what they most want from depression treatment, treating to target, measurement-based...

Read time: 4 min

Congress highlights

The Lancet Psychiatry Commission: A blueprint for protecting physical health in people with mental illness

The Lancet Psychiatry Commission: A blueprint for protecting physical health in people with mental...

Alzheimer's Disease

Read time: 2 min

Congress highlights

Why do star cells damage neurons in neurodegenerative diseases? New insights into Alzheimer’s disease pathogenesis

Why do star cells damage neurons in neurodegenerative diseases, including Alzheimer’s disease...

Read time: 3 min

Congress highlights

A public invitation to view and comment on pre-final APA schizophrenia guideline statements

Many guidelines exist worldwide on how best to manage psychiatric illnesses, but we never see two...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country